Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161158 | 0.69 | — | — | |
| SCHEMBL16471419 | 0.67 | TDP2 (0.50) | — | |
| SCHEMBL390083 | 0.67 | PARP10 (0.46) | CES1NOS3NOS2PNMT | |
| SCHEMBL61310 | 0.64 | CA12 (0.50) | CES1KMT2A | |
| SCHEMBL5186329 | 0.64 | PNMT (0.45) | CES1KMT2ANOS3NOS2PNMT | |
| SCHEMBL7342177 | 0.62 | AHR (0.52) | KMT2A | |
| SCHEMBL8936321 | 0.61 | CES1 (0.48) | CES1KMT2ANOS3NOS2PNMT | |
| SCHEMBL581339 | 0.61 | — | — | |
| SCHEMBL350515 | 0.60 | — | — | |
| SCHEMBL15763737 | 0.59 | NOS3 (0.52) | CES1NOS3NOS2PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373832-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | Context Biopharma Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240165077-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-11981636-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150288-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240139188-A1 | Arylamide Compounds For Treatment And Prevention Of Fungal Infections | INNOVATION PHARMACEUTICALS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3582779-B1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4337199-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20110071149-A1 | SELECTIVE KINASE INHIBITORS | REACTION BIOLOGY CORP. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011014880-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010118055-A1 | INHIBITORS OF COGNITIVE DECLINE | COGNITION THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010093808-A1 | SELECTIVE KINASE INHIBITORS | REACTION BIOLOGY CORP. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085597-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CES1 3692/4885KMT2A 382/4885NOS3 1155/4885 |
| US-20240150288-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, PSD | CES1 2978/4885KMT2A 3934/4885NOS3 2368/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | CES1 1543/4885KMT2A 3749/4885NOS3 2380/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | CES1 3363/4885KMT2A 1132/4885NOS3 2129/4885 |
| US-20110071149-A1 | SELECTIVE KINASE INHIBITORS | JAK3, JAK1, JAK2 | CES1 3797/4885KMT2A 1290/4885NOS3 335/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | CES1 2628/4885KMT2A 1266/4885NOS3 150/4885 |
| US-11981636-B2 | Compositions for treating neurodegenerative diseases | HTT, RTN3, RB1 | CES1 3601/4885KMT2A 2253/4885NOS3 109/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | CES1 1067/4885KMT2A 2682/4885NOS3 4096/4885 |
| US-20240139188-A1 | Arylamide Compounds For Treatment And Prevention Of Fungal Infections | NAT1, ERG28, AADAC | CES1 1570/4885KMT2A 1100/4885NOS3 993/4885 |
| US-20240165077-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES | SNCA, ACHE, PARK7 | CES1 3087/4885KMT2A 1256/4885NOS3 1790/4885 |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CES1 3692/4885KMT2A 382/4885NOS3 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.